Cabozantinib Plus Nivolumab Phase I Expansion Study in Metastatic Urothelial Carcinoma Patients Refractory to Immune Checkpoint Inhibitor Therapy
2018 ◽
Vol 36
(26)
◽
pp. 2743-2744
◽
2021 ◽
Vol 77
(18)
◽
pp. 3298